Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa
Pioneering Green Technology to Transform Food Security and Agricultural Productivity
Key Highlights:
Sustainable Agriculture Solution for AfricaDigital Utilities Ventures (DUTV) has secured a $3.4 million contract to deploy its patent pending Easy FEN™ modular units in Northern Africa. These advanced systems will convert 35,000 tons of biomass and food waste annually into 5.4 million gallons of Terreplenish®, an organic liquid microbial fertilizer. This initiative supports sustainable farming practices and enhances local food security by reducing reliance on costly synthetic fertilizers.
Proven Impact with Terreplenish®Backed by over 100 independent studies, Terreplenish® enhances soil fertility by providing essential nutrients like nitrogen and phosphorus, while boosting crop resilience. Farmers can expect reduced irrigation needs by up to 20% and minimized environmental damage compared to chemical fertilizers. These benefits contribute to improved crop yields and long-term soil health.
Tech-Driven, Scalable Agricultural InnovationThe Easy FEN™ units are remotely monitored from the U.S. to ensure reliable performance. By creating a self-sustaining business model, farmers can generate consistent revenue through the sale of Terreplenish®. With its scalable design, the system offers a viable solution for global food security challenges while reducing carbon footprints through waste conversion.
Positioning for Market GrowthWith the global fertilizer market projected at $381 billion in 2024, DUTV is strategically positioned for expansion. This contract highlights the company's commitment to climate resilience and economic development in emerging markets. Investors and stakeholders can expect further growth as the demand for sustainable agricultural solutions accelerates.MANKATO, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in regenerative agriculture and clean water technologies, today announced a $3.4 million contract for the sale and deployment of two Easy FEN™ modular units in Northern Africa. These patent-pending, state-of-the-art, fully automated systems will process up to 35,000 tons of biomass and food waste annually, converting it into 5.4 million gallons of Terreplenish®, a 100% organic, liquid microbial fertilizer designed to restore soil health and drive sustainable crop production.
With Africa facing critical food security challenges, the introduction of DUTV's Easy FEN™ units presents a scalable, financially sustainable solution that supports local agriculture while reducing reliance on costly imported synthetic fertilizers. The combined output of these units can treat up to 2.7 million acres (1.12 million hectares) of farmland per year, giving farmers an eco-friendly, cost-effective alternative to synthetic fertilizers—often subject to high import costs and extreme price volatility.An EasyFEN System in production in Mankato, MNFarmer in Somalia Applying Terreplenish Provided Through the Feed The Famished Program
Proven Impact: Terreplenish® for Soil Restoration and Higher Yields
DUTV's proprietary Terreplenish® has been validated through over 100 independent studies, proving its ability to enhance soil fertility, provide up to 60 pounds of nitrogen and 20 pounds of phosphorus per acre, and increase crop resilience against plant pathogens. Unlike chemical fertilizers that degrade soil and pollute waterways, Terreplenish® introduces live active microbes that naturally rebuild soil health, reduce irrigation needs by up to 20%, and mitigate environmental damage.
'With this contract, DUTV is delivering a transformational solution for African agriculture while generating strong revenue growth for our company,' said Mark K. Gaalswyk, CEO of DUTV. 'Our Easy FEN™ modular units provide a self-sustaining, scalable model for global food security—helping farmers improve yields while reducing environmental impact. This is just the beginning of what we see as a high-growth market for our proprietary agricultural technology.'
A Scalable, Tech-Driven Agricultural Solution
This contract marks the first deployment of American-made Easy FEN™ units, which will be remotely monitored from the U.S. to ensure consistent performance and quality control. Each unit will continuously produce microbial inoculants for ongoing sales through DUTV's Easy Modular Manufacturing subsidiary, creating a self-sustaining business model where buyers can quickly recover their investment through the sale of Terreplenish®. With the ability to generate millions of gallons of high-value organic fertilizer annually, Easy FEN™ systems offer not only an agricultural breakthrough but also a profitable revenue-generating opportunity for farmers and agribusinesses. By aligning economic opportunity with environmental sustainability, DUTV is advancing its mission to deliver cutting-edge solutions for agriculture and climate resilience.
More than just a technological breakthrough, this initiative represents the powerful intersection of humanitarian impact and economic opportunity. Africa, a continent facing severe food insecurity, is in critical need of sustainable agricultural solutions, as millions continue to suffer from starvation. By aligning the mission to end world hunger and reduce greenhouse gas emissions with a fully sustainable, investment-driven model, Easy FEN™ units offer a scalable, long-term solution for global agriculture.
A Strong Market Opportunity
The global fertilizers market was estimated at $381 billion in 2024 and is expected to show an average annual growth rate of more than 5.99% between 2024 and 2030. This trend can be explained by strong economic growth in emerging markets and increasing demand for organic food and natural agricultural products. Source: Global Fertilizer Market 2024
'This initiative is more than just a contract—it's a model for how technology can address food insecurity, climate challenges, and economic development simultaneously,' said Gaalswyk. 'We believe this is just the start of a much larger market opportunity for DUTV.'
About Digital Utilities Ventures, Inc.
Digital Utilities Ventures, Inc. (OTC: DUTV) is an innovative company developing modular technologies to solve major world problems. With a strong goal for sustainability and efficiency, DUTV aims to provide solutions for various industries through its unique approach to manufacturing and technology development.
Forward-Looking Statements
This press release contains discussions that may constitute 'forward-looking'' statements. Often these statements contain the words ''believe,'' ''estimate,'' ''project,'' ''expect'' or similar expressions. These statements are made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the United States Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
For information on Easy Energy Systems, Inc.: www.easyenergysystems.com
For information on Easy Energy Finance, Inc.: www.easyenergyfinance.com
For more information, please contact:
Mark K. Gaalswyk, CEOhttps://www.duventures.comPhone: 952-400-6045Email: info@duventures.com
SOURCE: Easy Energy Systems, Inc.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4034fd84-a9a0-44cb-bb3d-cb463e8a30ff
https://www.globenewswire.com/NewsRoom/AttachmentNg/de717402-4df9-4f6f-a89f-639f23fd564f
https://www.globenewswire.com/NewsRoom/AttachmentNg/02945907-7ad0-4d19-b438-f3e052e20296Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
30 minutes ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI
LONDON, June 9, 2025 /PRNewswire/ -- EthicAI Advisory Limited ("EthicAI"), a University of Cambridge spinout and global leader in the ethical and responsible assurance of artificial intelligence, has launched a cloud-based AI assurance SaaS platform to address ethical and trust issues around the adoption of AI, unlocking the technology's economic potential. AI models can create problems across a number of areas: Fairness and bias — AI systems can discriminate against certain groups including through hidden bias in training data Transparency — automating workflows can create 'black box' issues where algorithmic decision-making is opaque and consequently hard to understand and challenge Employee impacts — automation may unintentionally disempower, not augment, human workers if not designed carefully. The adoption of AI without enablement and literacy programmes can also erode company culture and employee motivation BeehAIve® scrutinises models and datasets against 15 ethical dimensions, assessing evidence across thousands of measurement points. The platform allows organisations to design, deploy and monitor autonomous systems that are optimised for success. BeehAIve® allows for technical stress-testing of model performance to improve reliability, robustness and security, while also recommending ways to reduce energy usage from AI. The platform enables assessment of models and systems against regional and national legislation including the EU AI Act, GDPR, the Korean AI Act, as well as industry-specific regulations and globally recognised AI standards. BeehAIve® then recommends how gaps can be filled, preparing for cross-border compliance while building stakeholder trust. The platform offers organisations a secure hub for their AI data, ensuring information remains safe and encrypted at all times. Tanya Goodin, Founder & CEO of EthicAI says: "BeehAIve® is a unique platform that enables organisations and their stakeholders to adopt AI with increased trust and confidence. Research shows that consumer confidence in AI has fallen by 8% globally over the past five years due to concerns about how AI is designed and built. BeehAIve® looks under the hood of organisations' AI models and systems — both in development and post deployment — to identify blind spots and weaknesses and provides actionable insights on how to mitigate and manage risks." For further information, contact: tanya@ or tim@ EthicAI Advisory Ltd EthicAI was formed in 2022 to build trust in AI by assuring models and systems to the highest ethical and responsible standards. EthicAI spun out of the University of Cambridge's Leverhulme Centre for the Future of Intelligence, with all the founding team previously engaged in cutting-edge AI ethics research at the university. The founders' leadership experience spans organisations including the BBC, Fidelity Investments, Barclays, Merrill Lynch, Deutsche Bank and UBS. Read more about the team here. EthicAI's cloud-based platform BeehAIve® will allow the company to scale its offer, and bring solutions to more organisations, more rapidly. It sits at the heart of the company's mission to ensure the ethical and responsible adoption of state-of-the-art AI systems — powering their success and helping to strengthen the UK's position as a leader in artificial intelligence. View original content: Sign in to access your portfolio
